Ascension | Sacred Heart Pensacola Oncology

Research site

About

Yazan Alsayed, M.D.; Alexander Brown, M.D.; Ranjith Dissanayake, M.D.; Dany El-Sayah, M.D.; Mose Hayes, M.D.; James Watkins, M.D.; Zachary Wright, M.D., F.A.C.P.

Location

1545 Airport Boulevard Ste 3000, Pensacola, Florida, United States of America

Website

https://healthcare.ascension.org/locations/florida/flpen/pensacola-ascension-sacred-heart-cancer-center/clinical-trials

Site insights

Top conditions

Top treatments

Pembrolizumab

Lenalidomide

Bevacizumab

Sacituzumab

Carboplatin

Paclitaxel

Nivolumab

S0931

Ramucirumab

LEE011

Parent organization

This site is a part of Ascension

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

6 of 33 total trials

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling

Relapsed/Refractory Follicular Lymphoma

Marginal Zone Lymphoma

Drug: Rituximab

Drug: Lenalidomide

Locations recently updated

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Active, not recruiting

Recurrent Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Biological: Pembrolizumab

Biological: Ramucirumab

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with u...

Active, not recruiting

Progressive Brain Metastasis

Unresectable or Metastatic Melanoma

Drug: Placebo in combination with nivolumab

Drug: HBI-8000 in combination with nivolumab

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Active, not recruiting

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vin...

Active, not recruiting

Large B-cell Lymphoma

Drug: Golcadomide

Drug: Doxorubicin